Patent Application Titled "Shp2 And Cdk4/6 Inhibitors Combination Therapies For The Treatment Of Cancer" Published Online (USPTO 20240293422).

A patent application has been published online discussing a combination therapy for the treatment of certain cancers. The therapy involves using a SHP2 inhibitor and a CDK4/6 inhibitor, which work together to provide a synergistic effect in treating cancer. The application mentions specific cancers that could potentially benefit from this therapy, such as colorectal cancer, non-small cell lung cancer, melanoma, and breast cancer. The application also discusses the use of a compound called alvociclib, administered orally, in combination with a CDK4/6 inhibitor for the treatment of cancer, particularly for cancers with a mutation in the KRAS gene. Different dosing schedules and other CDK4/6 inhibitors are also mentioned. This method can be used to treat various types of cancer, including colorectal cancer, non-small cell lung cancer, head and neck cancer, melanoma, and breast cancer. [Extracted from the article]